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Abstract: Human African trypanosomiasis (HAT) has
been a major public health problem in South Sudan for
the last century. Recurrent outbreaks with a repetitive
pattern of responding-scaling down activities have been
observed. Control measures for outbreak response were
reduced when the prevalence decreased and/or socio-
political crisis erupted, leading to a new increase in the
number of cases. This paper aims to raise international
awareness of the threat of another outbreak of sleeping
sickness in South Sudan. It is a review of the available
data, interventions over time, and current reports on the
status of HAT in South Sudan. Since 2006, control
interventions and treatments providing services for
sleeping sickness have been reduced. Access to HAT
diagnosis and treatment has been considerably dimin-
ished. The current status of control activities for HAT in
South Sudan could lead to a new outbreak of the disease
unless 1) the remaining competent personnel are used to
train younger staff to resume surveillance and treatment
in the centers where HAT activities have stopped, and 2)
control of HAT continues to be given priority even when
the number of cases has been substantially reduced.
Failure to implement an effective and sustainable system
for HAT control and surveillance will increase the risk of a
new epidemic. That would cause considerable suffering
for the affected population and would be an impediment
to the socioeconomic development of South Sudan.
Introduction
Human African trypanosomiasis (HAT), also known as sleeping
sickness, is a deadly disease caused by subspecies of Trypanosoma
brucei (Protozoa, Kinetoplastida)—T.b. gambiense and T.b. rhode-
siense—transmitted to humans through the bite of insect vectors of
the genus Glossina (tsetse flies) [1–5].
The disease has been a major public health problem in South
Sudan for the last century [6]. Foci due to T.b. gambiense have been
described in the Greater Equatoria Region bordering the Central
African Republic [7], Democratic Republic of the Congo [8,9],
and Uganda [10,11]. HAT caused by T.b. rhodesiense has been
reported from areas of Jonglei state (Akobo County) bordering
Gambella in Ethiopia [12,13], although since 1984 no HAT cases
have been reported from either Gambella or Jonglei [14].
In South Sudan, the main vector of the disease is Glossina fuscipes,
but G. tachinoides, G. pallidipes, and G. morsitans have also been found
in the Greater Equatoria Region [15–18].
Since the disease was first described in South Sudan, recurrent
outbreaks with a repetitive pattern of response-scaling-down
activities have been observed. Control measures for outbreak
response were reduced when the prevalence decreased and/or
socio-political crisis erupted, leading to a resurgence in the number
of cases. That pattern may now reoccur due to difficulties in
maintaining a high level of HAT control activities following the
recent decrease in prevalence. Decision makers should call for
urgent action to continue surveillance in order to avoid repeating
that pattern. This is essential to achieve sustainable control of the
disease.
South Sudan became a new nation in July 2011. The health
services are still in the building phase and so far, insecurity is
posing difficulties for health authorities and other implementers to
easily access some HAT-endemic areas.
This paper reviews the available data and the various
interventions over time, and reports on the current status of the
disease.
The authors seek to raise international awareness of the threat
of another sleeping sickness outbreak in South Sudan. To avoid
this, an innovative disease control and surveillance approach
needs to be developed. Failure to do so will inevitably result in a
flare up of the disease, thus causing unnecessary suffering and
significant interference with the socioeconomic development of
South Sudan.
Overview
1908–2000
Sleeping sickness was first reported from South Sudan in 1908
[19,20]. Between 1920 and 1925, more than 3,000 cases were
documented [21] (Figure 1). Control activities implemented from
1920 to 1950 brought the disease under control [22]. The civil war
that began in 1955 resulted in the interruption of HAT control
activities and a massive increase of the disease in the 1970s
influenced by a high influx of returnees and refugees from HAT-
endemic areas in Uganda. In 1974, this problem prompted the
Government of Sudan to ask the World Health Organization
(WHO) to assess HAT status. Active foci were identified and
control measures proposed. At that time, the German Caritas
Hospital in Nzara was the only center for sleeping sickness
treatment [23,24]. The joint Sudanese-Belgian Trypanosomiasis
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by the mid-1980s. Li-Rangu and Juba became reference centers
for HAT. Unfortunately, this program collapsed when the second
civil war broke out in 1983. Predictably, HAT prevalence
increased quickly, with the number of cases reported being higher
than ever before [25–28].
2001–2005 and 2006–2010
From the late 1990s to early 2000s, several non-governmental
organizations (NGOs) (namely Me ´decins Sans Frontie `res [MSF],
International Medical Corps [IMC], CARE International, Mal-
teser International, Samaritan’s Purse, and Medical Emergency
Relief International [MERLIN]) separately initiated HAT control
activities in South Sudan. These NGO programs provided access
to good quality case management, and they had the means to
carry out active screening, which is a key component for
controlling HAT. However, the NGOs were using different
diagnostic and treatment protocols and their databases were not
always accessible by the health authorities.
By 2005, there were 12 health facilities in Equatoria carrying
out HAT control activities, 11 of them run by NGOs and one—in
Juba—by the Ministry of Health (MoH). Active and passive
screening and treatment implemented despite the social and
armed conflict conditions under which they had to operate
resulted in more than 500,000 people screened and more than
16,000 patients treated between 1998 and 2005 (Figure 2). This
led to a significant decrease in the subsequent number of cases
reported [29].
This decrease in prevalence resulted in most NGOs progres-
sively stopping their activities after 2006, as it became difficult to
advocate for internal and external resources for what no longer
appeared to be a serious problem. By December 2010, only six
health facilities were still carrying out HAT control (in Tambura,
Yambio, Lui, Yei, Juba, and Nimule) and active screening had
ceased completely. Four facilities were run by the MoH and two
were run by NGOs (the Diocese of Lui, and MERLIN).
Since 2006, WHO has intensified its support for HAT control
through provision of technical assistance, drugs and screening
reagents, personnel training, and logistics.
Comparison of control activity statistics during the 5 years
following the departure of most NGOs (2006–2010) with the
previous period of peak NGO presence (2001–2005) shows a 47%
decrease in the number of people screened (from 399,977 to
211,946) and a 71% reduction in the number of new cases that
were reported (from 8,664 to 2,475) (Figure 3). The percentage of
screened people who underwent active screening was 70% in 2006
and fell to 8% in 2010. In 2006, 65% of new cases were in the
second stage of the disease, while in 2010 that percentage
increased to 76%.
HAT Status by County 2000–2010
Nine counties in Equatoria are endemic for HAT: Tambura,
Ezo, Yambio, Maridi, Ibba, Mundri, Yei, Kajo Keji, and Magwi,
representing a total population of 1.8 million according to the
2008 census (Figure 4). The 15,754 new cases reported from 692
locations between 2000 and 2009 have been mapped, and detailed
epidemiological information on the disease was provided down to
the village level [30]. Eight hospitals and five primary health care
centers had the capacity for diagnosis and treatment at one time or
another between 2000 and 2010, covering all the HAT-endemic
counties.
Tambura and Ezo Counties
From 1995 to 2000, IMC screened 66,759 people by active and
passive case detection, and identified 3,287 new cases and 601
relapses. From September 2000 to May 2002, CARE Interna-
tional provided support only for passive screening and treatment.
After May 2002, all activities ceased, treatment became unavail-
able, and in December 2003 the authorities of Tambura requested
WHO assistance to deal with the sleeping sickness problem. WHO
implemented a 6-month emergency program in 2004, offering
Figure 1. New cases of HAT reported in Sudan. Period 1910–2010.
doi:10.1371/journal.pntd.0001541.g001
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screened and 205 new cases and 29 relapses treated. WHO
advocated for a longer term partner to engage in HAT control,
and beginning in December 2004, MSF-Spain took over HAT
control activities in Tambura and Ezo Counties. In mid-2007,
MSF-Spain withdrew and HAT screening and treatment again
became unavailable, so that patients could only get treatment by
travelling to Yambio, some 200 km from Tambura. By mid-2010,
the MoH resumed passive screening and treatment of patients at
Tambura Hospital, and by the end of 2010, 234 people had been
passively screened, with eight new cases and three relapses
reported in Tambura.
Figure 2. Number of people screened and patients treated according to NGO and period of intervention.
doi:10.1371/journal.pntd.0001541.g002
Figure 3. Number of people screened and cases reported of HAT in South Sudan. Period 1997–2010.
doi:10.1371/journal.pntd.0001541.g003
www.plosntds.org 3 May 2012 | Volume 6 | Issue 5 | e1541Yambio County
From 2000 to 2006, the hospitals of Yambio, Li Rangu, or
Nzara had no capacity to provide diagnosis or treatment. HAT
patients from Yambio County could only be diagnosed and treated
in Ibba.
HAT diagnosis and treatment in Yambio Hospital were re-
established by MSF-Spain in October 2006, and when MSF-Spain
withdrew in February 2009, the MoH took over HAT services.
Between 2006 and 2009, 51,767 people were screened and 591
new cases treated.
In 2010, 1,041 people were screened and 37 new cases reported.
No relapses were reported.
Mundri, Ibba, and Maridi Counties
In 2000, the MSF-Holland HAT control program in Ibba was
handed over to MSF-France. Activities were progressively
extended to Maridi and Kotobi hospitals in 2001 and Lui hospital
in 2002. Over 170,000 people were screened and over 6,000 new
cases treated between 1999 and early 2006 in these three counties
[32]. The last active screening was carried out in Ibba and Maridi
in 2004, where the overall prevalence found was below 1%,
although in two locations—Baama and Maribindi—the preva-
lence was above 1%. In Mundri County, prevalence was higher
than 1% in five locations (Lanyi, Amadi, Diko, Nyau, and Kalalai)
in 2004 and 2005 when the last active screening was carried out by
MSF-France.
When MSF-France withdrew from the area in March 2006,
active case finding ceased: Ibba and Kotobi HAT centers were
closed, and the Maridi and Lui hospitals stopped treatment for
second-stage HAT. Later in 2006, both hospitals also discontinued
treatment of first-stage disease. Patients had to travel some 200–
300 km to seek HAT medical care either in Yambio, Juba, or Yei.
In 2008, a rapid epidemiological assessment was carried out by
WHO and the Diocese of Lui in seven villages (Lozoh,
Milikolongo, Mundri, Ndibo, Amadi, Osho, and Jambo) in
Mundri County. The assessment showed a prevalence of 0.46%
(eight cases out of 1,722 people screened). No active screening has
been carried out in those villages since then.
As of today, Maridi hospital has neither resumed diagnosis nor
treatment of sleeping sickness.
In September 2007, representatives of Lui hospital, managed by
the Diocese of Lui, contacted WHO to request support to resume
HAT medical services in their center. HAT diagnosis and
treatment were made available, including treatment for second-
stage patients for the first time in that hospital. From 2007 to 2009,
over 9,000 people were passively screened in Lui hospital and 223
new cases and 113 relapses were treated, including 35 patients
previously treated in Lui and 78 treated in other treatment centers.
In Lui hospital in 2010, 1,406 people were screened and 44 new
cases and 52 relapses (28 previously treated in Lui and 24 in other
centers) reported. An in-depth analysis should be done to precisely
identify the reasons behind that high relapse rate in Lui hospital.
Kajo Keji County
When MSF-Switzerland initiated a HAT control program in
2000 in Kajo Keji County, they built a HAT hospital in Kiri. In
2004, when the overall prevalence found during active screening
had decreased to 0.7%, HAT activities were moved to the Kajo
Keji hospital, where 20 beds were allocated for the disease. In
2005, prevalence detected during active screening was 0.3% and
MSF-Switzerland stopped its activities there in 2006. From 2000
to 2006, over 170,000 people were screened and around 3,500
cases were diagnosed and treated [33–35].
In September 2006, IMC took over HAT activities from MSF-
Switzerland in Kajo Keji hospital. During 2007–2008, IMC
screened 20,098 people and treated 64 new cases. IMC ceased
HAT medical services in October 2008, and to date the County
Health Department (CHD) has not resumed these activities. Since
then, several cases coming from Kajo Keji have been diagnosed in
Nimule, Yei, and Juba and even in bordering HAT centers in
Uganda (Moyo hospital). No active screening has been performed
in the county since 2008.
Yei County (including Lainya and Morobo)
In 2000 and 2001, cases of HAT coming from Yei were
diagnosed and treated in Ibba and Omugo (Uganda). A rapid
epidemiological assessment performed by Malteser International
with support of the WHO in 2001 provided estimates of HAT
prevalence at around 4% to 7% in some highly endemic villages in
Yei County. Malteser International started implementing HAT
control activities in Yei in March 2002 at the St. Bakhita Health
Centre on the premises of the Diocese of Yei. A specific ward and
laboratory for HAT were set up. From 2002 until 2005, more than
130,000 people were screened and 1,592 new cases detected and
Figure 4. Areas reporting cases of HAT in South Sudan. Period 2000–2009.
doi:10.1371/journal.pntd.0001541.g004
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dropped from 4.03% in 2002 to 0.38% in 2005.
Between 2006 and 2009, 49,610 people were screened and 437
new cases reported. In mid-2010, Malteser International handed
over the HAT control activities to Yei Civil Hospital run by the
MoH.
In 2010, 1,771 people were passively screened, and 73 new
cases and four relapses reported and treated.
Juba County
In the late 1990s and early 2000s, occasional cases (3–6 per
year) coming from internally displaced people or military camps
were diagnosed in Juba Teaching Hospital (JTH). In 2002, an
active screening survey carried out by the Tropical Medicine
Research Institute-TMRI (Khartoum) on 2,344 individuals in 13
locations showed a CATT whole blood seroprevalence of 11% but
no serological suspect was parasitologically confirmed. In 2003, a
joint WHO/TMRI active screening survey in six locations,
including internally displaced people camps, showed a seroprev-
alence of 4% and a parasitological prevalence of 0.13% (3/2,374).
Between 2006 and 2009, 450 people were screened at JTH and
90 new cases reported, most coming from Mundri County.
In 2010, 18 people were screened and nine new cases reported,
mainly coming from neighboring counties.
Magwi County
Between 2000 and 2005, sporadic cases from Magwi County
were diagnosed and treated in Kajo Keji. In March 2005,
MERLIN started HAT control activities in Magwi County, and a
rapid assessment in 16 villages showed an overall prevalence of 1%
(25/2,481).
MERLIN continues to provide support to all medical services at
Nimule hospital including HAT. From 2005 to 2009, 39,043
people were screened and 703 new cases reported.
In 2010, 1309 people were screened, with 29 new cases and six
relapses reported.
Case Management
South Sudan was the first place where eflornithine was used on
a large scale as first line treatment for second-stage HAT patients.
The decision was made due to melarsoprol toxicity [36–38] and an
increased relapse rate observed with melarsoprol in some areas of
South Sudan [39–40] and neighbouring foci in Uganda [41].
Treatment with eflornithine was found to be safer [42], and
melarsoprol treatment was progressively replaced by eflornithine
as first line treatment for second-stage HAT.
Eflornithine treatment was introduced in 2001 by MSF-France
in Maridi [43,44] (Ibba and Kotobbi hospitals), in 2002 by
Malteser in Yei [45,46], in 2004 by MSF-Switzerland in Kajo-Keji
[47], in 2004 by the WHO-supported treatment center in
Tambura, in 2005 by MERLIN in Magwi [48], in 2007 by the
Diocese of Lui, and in 2010 by the MoH in Juba. All drugs to treat
HAT were made available free of charge by WHO through
public/private agreements between WHO and the manufacturers
[49].
Data on eflornithine effectiveness in 944 new cases treated in
the period 2002–2005 was reviewed by WHO in collaboration
with NGO partners from Yei and Kajo Keji hospitals showing a
9% (8%–11%) relapse rate (unpublished data).
In mid-2010, nifurtimox-eflornithine combination therapy
(NECT) [50] was introduced as the new first line for second-
stage treatment in South Sudan, shortly after the inclusion of that
treatment regimen in the 2009 WHO Model List of Essential
Medicines [51]. A training of trainers was organized by WHO for
key staff in all HAT centers.
Vector Control
HAT control activities in South Sudan focused on active and
passive case detection and prompt treatment of cases. Some short-
term vector control activities were implemented in selected areas
by Malteser International in Yei and CARE International in
Tambura [52].
Monitoring and Surveillance
Coordination between the MoH, WHO, and NGOs took place
from 2003 to 2008 through HAT annual review meetings held to
discuss achievements and challenges in the control of the disease.
These meetings were discontinued in mid-2008. A standardized
HAT monthly reporting form was created in 2007 and became
part of the Integrated Disease Surveillance and Response
information system. Despite this reporting system, obtaining
regular data at the central level remains a major challenge.
Institutional Framework
HAT control and surveillance are within the mandate of the
Director General of Community and Public Health in the MoH–
Republic of South Sudan (RSS) [53]. The MoH-RSS is
responsible for policy making, technical guidance, and overall
coordination, whereas implementation of control activities is the
responsibility of the State Ministries of Health (SMoH) and the
CHDs. Three SMoH are involved in the implementation of HAT
activities—Eastern, Central, and Western Equatoria—but these
ministries and departments have so far been unable to take over
the control activities carried out in the past by NGOs. The
substantial decrease in the number of people screened reflects this
weakness of the health system.
Conclusions
From the mid-1990s until 2005, large-scale HAT control
activities in South Sudan were carried out by NGOs, leading to an
important decrease in the number of cases that caused a
progressive withdrawal of NGOs involved in HAT control. From
2006 onward, control interventions and treatment centers
providing services for sleeping sickness have been reduced, and
population access to HAT diagnosis and treatment has been
considerably diminished. Epidemiological history shows that such
a situation could lead to a new epidemic, and it may be that an
unreported resurgence of disease is already occurring. That idea is
supported by the 2010 figures, where 92% of the screening was
done passively and 76% of patients were diagnosed as already with
second-stage disease. Since most HAT first-stage patients are
asymptomatic, or present with symptoms mimicking other
common diseases such as malaria, they are usually diagnosed in
higher numbers through active screening. Meanwhile, those
actually infected and not being treated act as a reservoir,
maintaining the transmission cycle.
The risk of a new epidemic is aggravated by four facts:
(1) Reduced HAT control activities result in diminishing local
capacity for the control of sleeping sickness, unless the
remaining competence is used to train younger staff to resume
HAT surveillance and control activities.
(2) The directorate responsible for HAT control is also in charge
of other communicable diseases and reporting recurrent
www.plosntds.org 5 May 2012 | Volume 6 | Issue 5 | e1541outbreaks, such as cholera, meningitis, and visceral leishman-
iasis. As a result, it becomes difficult to keep HAT, with a less
‘‘visible’’ progression, on the top of the agenda at a time when
the number of cases has been substantially reduced and the
disease is thus not regarded as a major public health problem.
(3) Most NGOs who have been active in HAT control are
focused on providing medical aid in emergency situations.
The situation of HAT does not currently qualify as a public
health emergency.
(4) The health system of South Sudan is not yet consolidated and
consequently not able to fully take over the control activities
carried out in the past by NGOs. Having been unsuccessful in
convincing most NGOs to continue their control activities in
the region, the WHO is now strengthening SMOH and CHD
capacity to allow them to fill this role.
Strengthening current HAT control and surveillance capacity
and activities includes the following:
i) reinforcing selected health care facilities to deliver HAT
diagnosis and treatment; ii) improving the HAT surveillance
system by ensuring passive screening and reporting to the central
level; iii) reinforcing central level for management and data
analysis; and iv) establishment of a national team that can respond
to the possible re-emergence of the disease, as deduced from the
data from passive screening with targeted active case search in the
affected areas.
Failure to implement an effective and sustainable system for
HAT control and surveillance will pose a high risk of HAT
resurgence, which would cause immeasurable suffering for the
affected population and would be an impediment to the
socioeconomic development of South Sudan.
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